Daré Bioscience and Orbis Biosciences have agreed to collaborate on development of two etonogestrel-based injectable contraceptives. The products under development will target 6- and 12-month durations of efficacy, improved side effect profiles compared to current injectables, and a more predictable return to fertility. Currently marketed injectables provide three months of contraceptive protection. The collaboration will leverage pre-clinical studies completed on this concept under the FHI 360-led Contraceptive Technology Innovation Initiative, supported by the Bill & Melinda Gates Foundation.